Evaluation of Fracture Fixation With Energy and Cement in Tumors of the Spine
NCT ID: NCT00594321
Last Updated: 2012-09-03
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
WITHDRAWN
NA
INTERVENTIONAL
2007-07-31
2009-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Keywords
Explore important study keywords that can help with search, categorization, and topic discovery.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
2
Subjects randomized to the control arm of the study will have a standard vertebroplasty with any FDA-approved bone cement done in accordance with the usual method employed by the treating physician.
standard vertebroplasty
standard vertebroplasty
1
Subjects randomized to the experimental arm of the study will have a vertebroplasty with the SPACE CpsXL Bone cement (FDA-approved) and SPACE 360 Delivery System (FDA-approved).
SPACE CpsXL Bone Cement and SPACE 360 Delivery System
SPACE CpsXL Bone Cement and SPACE 360 Delivery System
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
SPACE CpsXL Bone Cement and SPACE 360 Delivery System
SPACE CpsXL Bone Cement and SPACE 360 Delivery System
standard vertebroplasty
standard vertebroplasty
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Pain at one to three levels, or five for multiple myeloma (pain on palpation/percussion over fractured vertebral body) requiring treatment
3. Spinal metastasis (except renal cell), myeloma, or lymphoma of the spine
4. Pathological fracture(s), T5-L5, with bone marrow edema imaged by magnetic resonance imaging (MRI)
5. Visual Analog Scale (VAS) for pain of \> 4 on a scale of 0 to 10
6. Oswestry score of at least a moderate disability (21-40%)
7. No major surgery to the spine planned for at least 1 month following enrollment - Defined as a procedure the magnitude of a laminectomy or more
8. Life expectancy of \> 6 months.
9. Patient has sufficient mental capacity to comply with the protocol requirements
10. Availability for all study visits and phone calls
11. Understands the potential risks and benefits of participating in the study and is willing to provide written informed consent
12. Pathological vertebral fracture with 20-70% compression (compared to adjacent normal vertebral body)
13. Fracture age \< 6 months
14. Signal on MRI consistent with non-healed fracture
15. Female subjects must either be no longer capable of reproduction or taking acceptable measures to prevent pregnancy during the study
16. Subject must be willing and able to comply with specified follow-up evaluations
Exclusion Criteria
2. Renal cell tumors
3. More than 80% compression of the vertebrae
4. Level(s) above T7 to treat
5. Fractures due osteoporosis
6. Burst fracture
7. Pedicle fracture
8. Neurological deficit associated with the fracture
9. Kyphosis \> 30°
10. Translation \> 4 mm
11. Instability of posterior wall with symptomatic displacement of fragment into spinal canal or significant canal compromise
12. Intercostal nerve compression
13. Active systemic or local infection at the level(s) to be treated
14. Myelopathy
15. Uncontrolled coagulopathy
16. Cannot temporarily discontinue anticoagulation therapy
17. Known allergy to device materials / PMMA
18. Radiculopathy
19. Cord compression or canal compromise requiring surgery for decompression
20. High energy trauma
21. Severe cardiopulmonary deficiencies - Defined as not being able to tolerate general anesthesia (although the likelihood is local anesthesia will be used)
22. Vertebra plana defined as vertebral body height of 20% or less compared to the nearest normal level
23. Disabling back pain secondary to another cause that may interfere with accurate data collection
24. Subjects who are known to be pregnant (pregnancy test required within 10 days of treatment) or lactating
25. Females capable of reproduction and will not take acceptable measures to prevent reproduction during the study
26. Subjects who test positive for HIV
27. Currently enrolled in another investigational device trial (IDE) that has not completed the protocol required primary follow-up period (excludes 15 year follow-up of gene therapy trials)
28. Lesions involving the pedicle
29. Platelet count of \< 50,000
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of California, Davis
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Arthur B. Dublin, M.D.
Role: PRINCIPAL_INVESTIGATOR
UC Davis Dept. of Radiology
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
UC Davis Medical Center
Sacramento, California, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
200715482
Identifier Type: -
Identifier Source: org_study_id